Arrow Therapeutics

When Glaxo merged with Wellcome in 1995, Ken Powell, then head of biology at Wellcome, turned down the job of heading research in the UK for the new company in favor of "something new." He has since been involved in a series of start-up companies, of which Arrow Therapeutics Ltd. , is the latest. Powell set up Arrow with four other Wellcome scientists and one academic to develop new anti-infective compounds which overcome the growing problem of resistance. An extensive network of academic and commercial collaborations, as well as in-house expertise, give Arrow access to a range of robust, practical technologies covering all the steps from target discovery to lead optimization and preclinical development. The company already has one compound scheduled to enter clinical trials next year, five development programs, and a development deal with Triangle Pharmaceuticals Inc. [See Deal]

Arrow's approach to discovering new drug targets begins with its transposon-mediated differential hybridization (TMDH) technology, which it uses to scan...